Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melanoderm
- Development stage
- Unknown
- Lead developer
- Mesoestetic
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Melanoderm is a topical depigmenting cream containing 4% hydroquinone, developed by Mesoestetic Pharma Group for the treatment of facial melasma. Hydroquinone, the active ingredient, works by inhibiting the enzyme tyrosinase, which is essential for the synthesis of melanin in melanocytes. By reducing melanin production, it helps lighten hyperpigmented areas of the skin. The efficacy and safety of Melanoderm 4% have been evaluated in Phase 3 clinical trials (e.g., NCT02095990) using the Melasma Area and Severity Index (MASI) score to assess changes in pigmentation and patient satisfaction.
- Brand names
- MelanodermMelanoderm 4% Crema
- Other names
- Melanoderm 4%
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on Melanoderm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoderm.